We are live on ! Find out more
CMPX icon

Compass Therapeutics

78 hedge funds and large institutions have $187M invested in Compass Therapeutics in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 35 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more capital invested

Capital invested by funds: $135M → $187M (+$52.5M)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

1% more funds holding

Funds holding: 7778 (+1)

1% more ownership

Funds ownership: 67.72%68.72% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

49% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 35

Holders
78
Holders Change
+1
Holders Change %
+1.3%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
9
Increased
18
Reduced
35
Closed
8
Calls
Puts
Net Calls
Net Calls Change

CMPX Hedge Fund Activity: Q1 2024 in Review

78 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2024, worth a combined $187M — up 39% from $135M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CMPX positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 35 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $9.61M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $2.5M sold.

  • 78 institutional investors held Compass Therapeutics (CMPX) as of Q1 2024, up from 77 in Q4 2023.
  • Funds reported $187M of Compass Therapeutics stock for Q1 2024, up 39% quarter-over-quarter.
  • 9 funds opened new Compass Therapeutics positions in Q1 2024 and 8 closed out, a net change of +1 holder.
  • The largest Compass Therapeutics buyer in Q1 2024 was Cormorant Asset Management, an estimated $9.61M added.
  • The largest Compass Therapeutics seller in Q1 2024 was Avidity Partners Management, an estimated $2.5M sold.

Based on aggregated 13F filings for Q1 2024.